Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Philippe Moreau Meletios A Dimopoulos Kwee Yong Joseph Mikhael Marie-Laure Risse Ga ëlle Asset Thomas Martin Source Type: research